Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL517553 | 0.98 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR1ANAAA | |
| SCHEMBL624855 | 0.87 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3HTR1AHRH1 | |
| Hydrochloric Acid SCHEMBL795619 | 0.85 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR1AHRH1 | |
| SCHEMBL2300957 | 0.83 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3HTR1AHRH1 | |
| SCHEMBL6608784 | 0.81 | NAAA (0.58) | SLC6A4SLC6A2SLC6A3NAAAHRH1 | |
| SCHEMBL5204218 | 0.81 | HRH1 (0.79) | SLC6A4SLC6A2SLC6A3HTR1ANAAA | |
| SCHEMBL19334368 | 0.79 | HRH1 (0.64) | SLC6A4SLC6A2SLC6A3HTR1AHRH1 | |
| Oxalic Acid SCHEMBL9595892 | 0.78 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR1AHRH1 | |
| SCHEMBL2582519 | 0.77 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3HTR1AHRH1 | |
| SCHEMBL13703555 | 0.77 | HRH1 (0.71) | SLC6A4SLC6A2SLC6A3HTR1ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918640-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | disclosed |
| EP-2265578-B1 | AZETIDINE DERIVATIVES | VERNALIS R&D LTD (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | disclosed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20120028953-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2012-02-02 | — | — | US | disclosed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | disclosed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918640-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | SLC6A4 750/4885SLC6A2 1145/4885SLC6A3 869/4885 |
| US-20120028953-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | SLC6A4 719/4885SLC6A2 1159/4885SLC6A3 792/4885 |
| US-20150183769-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | SLC6A4 746/4885SLC6A2 1209/4885SLC6A3 994/4885 |
| US-20170196864-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | SLC6A4 750/4885SLC6A2 1145/4885SLC6A3 869/4885 |
| US-10383871-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | SLC6A4 750/4885SLC6A2 1145/4885SLC6A3 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.